Solventum Corporation $SOLV Shares Sold by Osaic Holdings Inc.

Osaic Holdings Inc. cut its holdings in shares of Solventum Corporation (NYSE:SOLV) by 13.8% in the second quarter, HoldingsChannel reports. The firm owned 42,355 shares of the company’s stock after selling 6,790 shares during the period. Osaic Holdings Inc.’s holdings in Solventum were worth $3,212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its holdings in shares of Solventum by 226.2% in the 1st quarter. Wellington Management Group LLP now owns 27,737 shares of the company’s stock valued at $2,109,000 after buying an additional 19,233 shares during the period. CW Advisors LLC acquired a new stake in Solventum during the first quarter worth about $312,000. Smartleaf Asset Management LLC raised its position in Solventum by 193.4% during the first quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock valued at $40,000 after acquiring an additional 352 shares in the last quarter. Comerica Bank lifted its holdings in Solventum by 39.7% in the first quarter. Comerica Bank now owns 77,725 shares of the company’s stock valued at $5,910,000 after acquiring an additional 22,079 shares during the period. Finally, FORA Capital LLC acquired a new position in Solventum in the first quarter valued at approximately $676,000.

Solventum Stock Performance

NYSE:SOLV opened at $80.18 on Friday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50. The company has a fifty day moving average of $77.56 and a two-hundred day moving average of $74.83. The stock has a market capitalization of $13.91 billion, a PE ratio of 9.24, a P/E/G ratio of 8.46 and a beta of 0.26. Solventum Corporation has a fifty-two week low of $60.70 and a fifty-two week high of $88.20.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The business had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.05 billion. During the same quarter in the previous year, the company earned $1.64 earnings per share. The company’s quarterly revenue was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. As a group, research analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Solventum declared that its board has authorized a stock repurchase plan on Thursday, November 20th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 7.5% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

A number of brokerages have recently commented on SOLV. UBS Group reaffirmed a “neutral” rating on shares of Solventum in a research note on Friday, November 21st. BTIG Research upgraded shares of Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Tuesday, December 2nd. Wall Street Zen raised shares of Solventum from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Zacks Research downgraded shares of Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. Finally, Piper Sandler reissued an “overweight” rating on shares of Solventum in a research note on Wednesday, December 17th. Four equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $87.00.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.